Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

Eli Lilly & Company (NYSE: LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Eli Lilly and Company (NYSE:LLY) is one of the top low volatility healthcare stocks to buy now. On July 10, Morgan Stanley ...

An expert committee recommended that the drug be offered to a narrow group of patients with early-stage Alzheimer’s ...

Get the latest business headlines including trade deals, AI in airlines, and the surprising comeback of cottage cheese. Stay ...

The trial drug Trontinemab is designed to bypass the blood brain barrier, delivering more treatment directly to the brain.

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

(Reuters) -Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease ...

China is the fourth major market where Kisunla has received approval . Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, as a part of the company's growing development programmefor the ...